Qing Yi, M.D., Ph.D.
The Methodist Hospital Research Institute
|Titles & Positions|
|Institutional & Related Links|
|Grant ID: RR180044|
Recruitment of Established Investigators
Lerner Research Institute - Cleveland Clinic
May 16, 2018
Multiple myeloma is the second-most common blood cancer after non-Hodgkins lymphoma. Although it boasts a five-year survival rate of 50%, most patients eventually die from relapse of the disease.
Now a researcher at Houston Methodist Research Institute is trying to develop immune therapy for multiple myeloma that might provide patients with a better choice of treatment for their disease.
Dr. Qing Yi, who chaired the department of cancer biology at the Cleveland Clinic Lerner Research Institute, returns to Texas as Associate Director of the Houston Methodist Research Institute and Director of the Research Center for Hematologic Malignancies. He was recruited with the help of an Established Investigator Award from CPRIT. Dr. Yi was formerly a tenured professor of medicine at The University of Texas MD Anderson Cancer Center.